AC Immune (ACIU) Non-Current Receivables (2024 - 2025)
AC Immune (ACIU) reported Non-Current Receivables of $3753.5 for Q4 2025, down 17.8% year-over-year from $4566.1 in Q4 2024, and down 17.8% on a QoQ basis from $4566.1 in Q4 2024.
AC Immune (ACIU) has 2 years of Non-Current Receivables data on file, last reported at $3753.5 in Q4 2025.
- Quarterly Non-Current Receivables fell 17.8% year-over-year to $3753.5 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3753.5 (down 17.8% YoY) and the FY2025 annual result came in at $3618.4, down 20.76% from the prior year.
- Non-Current Receivables retreated to $3753.5 in Q4 2025 per ACIU's latest filing, from $4566.1 in the prior quarter.
- Across five years, Non-Current Receivables topped out at $4566.1 in Q4 2024 and bottomed at $3753.5 in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.49 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | AC Immune | 325.88 Mn | 211.53 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3,753.51 |
| Dec 31, 2024 | 4,566.09 |